Proteomic analysis for elucidation of individual differences in chemotherapeutic response and for biomarker development

我们应用蛋白质组学方法来阐明人类结直肠癌细胞化疗反应的个体差异，并开发用于预测化疗敏感性的蛋白质生物标志物。我们已经鉴定出蛋白质 S100A10，其表达与奥沙利铂敏感性密切相关，我们的研究结果表明该蛋白质是临床环境中的潜在生物标志物。此外，我们还发现了几种蛋白质作为潜在的生物标志物，可以预测抗癌药物（如 5-氟尿嘧啶和伊立替康的活性代谢物）的敏感性。

We applied proteomic approach to elucidate individual differences in chemotherapeutic response of human colorectal cancer cells and to develop protein biomarkers for predicting chemosensitivity. We have identified the protein S100A10 whose expression well correlated with sensitivity to oxaliplatin, and our findings suggested this protein a potential biomarker in clinical setting. Furthermore, we have also found several proteins as potential biomarkers to predict sensitivity to anticancer drugs such as 5-fluorouracil and active metabolite of irinotecan.